OBJECTIVE: To compare the efficacy of adjuvant chemoradiotherapy (CRT) and @entity7730 ( @entity7730 ) in @entity356 @entity1 undergoing gastrectomy in the @entity3290 ( @entity3290 ). BACKGROUND: A majority of @entity3290 @entity356 @entity1 are inadequately staged (<15 nodes examined). Despite this, and limited data comparing adjuvant CRT with @entity7730 in @entity3290 @entity1 , national guidelines endorse @entity7730 in selected @entity1 undergoing D2 lymphadenectomy. METHODS: Resected stage IB-III @entity356 @entity1 receiving adjuvant CRT or @entity7730 (n = 3008) were identified in the National @entity5 Database (1998-2006). Cox regression identified covariates associated with @entity1349 ( @entity1349 ). CRT and @entity7730 cohorts were matched (3:1) by propensity scores based on the likelihood of receiving @entity7730 . @entity1349 was compared by Kaplan-Meier estimates. RESULTS: Adjuvant @entity7730 was associated with an increased risk of @entity204 (HR 1.29, P < 0.001) relative to CRT. Inadequate lymph node staging (LNS) and nodal positivity were strong predictors of risk-adjusted mortality (P < 0.001). After propensity score-matching, CRT demonstrated superior median @entity1349 compared with @entity7730 (36.1 vs 28.9 m; P < 0.0001), regardless of stage. CRT was superior to @entity7730 in inadequately staged @entity1 (33.1m vs 24.5 m; P < 0.001); this benefit was less pronounced with increasing nodal examination. CRT improved @entity1349 in node-positive disease (29.8 vs 22.2 m; P < 0.001), regardless of LNS adequacy. In node-negative disease, @entity1349 did not differ significantly between CRT and @entity7730 cohorts; however, node-negative @entity1 undergoing inadequate LNS benefited from CRT. CONCLUSIONS: CRT is associated with improved stage-stratified @entity1349 compared with @entity7730 . Lymph node status and adequacy of surgical staging should influence adjuvant therapy selection in the @entity3290 .

Implications of Lymph Node Staging on Selection of Adjuvant Therapy for XXXX in the @entity3290 : A Propensity Score-matched Analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity7730 :: ('MESH:D064146', 'Disease') :: ['chemotherapy alone', 'CA'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity3290 :: ('MESH:D062706', 'Disease') :: ['US', 'United States'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity356 :: (MESH:D013274,Disease) :: ['Gastric Cancer']
